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Retinal neovascularization is a major cause of blindness and re-
quires the activities of several signaling pathways and multiple
cytokines. Activation of protein kinase C (PKC) enhances the
angiogenic process and is involved in the signaling of vascular
endothelial growth factor (VEGF). We have demonstrated a dra-
matic increase in the angiogenic response to oxygen-induced
retinal ischemia in transgenic mice overexpressing PKC2 isoform
and a significant decrease in retinal neovascularization in PKC
isoform null mice. The mitogenic action of VEGF, a potent hypoxia-
induced angiogenic factor, was increased by 2-fold in retinal
endothelial cells by the overexpression of PKC1 or 2 isoforms
and inhibited significantly by the overexpression of a dominant-
negative PKC2 isoform but not by the expression of PKC , , and
 isoforms. Association of PKC2 isoform with retinoblastoma
protein was discovered in retinal endothelial cells, and PKC2
isoform increased retinoblastoma phosphorylation under basal
and VEGF-stimulated conditions. The potential functional conse-
quences of PKC-induced retinoblastoma phosphorylation could
include enhanced E2 promoter binding factor transcriptional ac-
tivity and increased VEGF-induced endothelial cell proliferation.
Protein kinase C (PKC) activation enhances angiogenesis byparticipating in the intracellular signaling of vascular endo-
thelial growth factor (VEGF) in endothelial cells (1–3). VEGF,
a potent angiogenic factor that is induced by hypoxia plays a
central role in the development of neovascularization in multiple
diseases including tumor growth (4, 5), rheumatoid arthritis (6),
and proliferative diabetic retinopathy (7, 8). VEGF can activate
several PKC isoforms including , 1 and 2, and  isoforms (2,
7). Involvement of PKC activation in VEGF action has also been
suggested by the use of a PKC isoform selective inhibitor, which
decreased VEGF-induced endothelial cell proliferation and
retinal vascular permeability (2, 7). However, definitive in vivo
evidence on the role of specific PKC isoforms with regard to
hypoxia-induced angiogenesis is not available. In addition, the
potential signaling mechanism by which PKC isoforms are acting
to enhance VEGF-induced endothelial cell proliferation is
unknown.
Materials and Methods
Mice. Linearized PEP8-PKC2 DNA was used to derive trans-
genic mice as described (9–11). PKC2 cDNA probe was used
to examine the incorporation of the transgene. Transgene ex-
pression was confirmed by Northern blot and immunoblot on
heart, aorta, and retina. Founders were bred with C57BL6 mice
and F1 mice were used for experiments. PKC null mice have
been described previously (12).
Ischemia-Induced Proliferative Retinopathy. The study adhered to
the Association for Research in Vision and Ophthalmology
statement for the Use of Animals in Ophthalmic and Vision
Research. Postnatal day 7 (P7) mice and their nursing mothers
were exposed to 75  2% oxygen for 5 days to induce and then
returned to room air inducing retinal vaso-obliteration. Maxi-
mum neovascularization was observed at P17. Flat-mounted,
f luorescein-conjugated dextran-perfused retinas were examined
to assess the retinal vasculature (see refs. 13 and 14) .
Quantitation of Neovascularization. Mice at P17 were killed and
eyes enucleated, fixed, and embedded in paraffin. Fifty serial
sections (6 m) starting at the optic nerve head were placed on
microscope slides. After staining with periodic acidSchiff re-
agent and hematoxylin, 10 intact sections of equal length, each
30 m apart, were evaluated for a span of 300 m. All retinal
vascular cell nuclei anterior to the internal limiting membrane
were counted in each section by a fully masked protocol. The
mean of all 10 counted sections yielded average neovascular cell
nuclei per 6-m section per eye (see refs. 13 and 14).
Northern and Western Blot Analysis. Total RNA or protein from
8–10 retinas at P14 was assessed by Northern (15) or Western
(16) blot analysis as described.
Cell Culture. Primary cultures of bovine retinal endothelial cells
(BREC) were isolated and cultured as described (17). Only cells
from passages 2–7 were used for the experiments.
Recombinant Adenoviruses. cDNA of dominant-negative PKCs
was constructed as described (18–21). The replication-deficient
recombinant adenoviruses were constructed by homologous
recombination between the parental virus genome and shuttle
vector as described (22). The dominant-negatives of PKC2
isoform were constructed by converting threonine-500 to valine
which caused the PKC isoform to become kinase-inactive. The
adenoviruses were applied at a concentration of 1  108
plaque-forming units/ml, and adenoviruses with the same
parental genome carrying enhanced green fluorescent protein
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(GFP) gene (CLONTECH) were used as controls. Infection
efficiency was monitored by fluorescence which showed expres-
sion in 80% of cells. Expression of each recombinant protein
was confirmed by Western blot analysis of each PKC isoform.
Both the wild types and their respective dominant-negative
isoforms exhibited increases 8- to 10-fold above the endogenous
isoforms by protein levels.
Cell Growth Assay. BREC were plated onto 12-well culture plates
and incubated overnight in DMEM containing 10% calf serum,
after which the cells were infected with adenovirus (23). After
incubation for 4 days at 37°C with or without VEGF (0.6 nM),
the cells were lysed in 0.1% SDS, and the DNA content was
measured by means of Hoechst-33258 dye and a fluorometer
(model TKO-100, Hoefer). E2 promoter binding factor (E2F)
decoys were used as described (24).
Cell Migration Assay. A modified Boyden chamber migration assay
was performed by using BREC (25). The top and bottom surface
of the chamber membrane was coated with collagen I. Serum-
starved BREC overexpressing each PKC isoform were induced
to migrate toward VEGF (0.6 nM) placed in the bottom chamber
and harvested after 4 h. Cells that migrated to the bottom of the
chamber were enumerated by counting SYTOX green (Molec-
ular Probes) nucleic acid-stained cells.
In Vitro Phosphorylation of Retinoblastoma (Rb) Protein. In vitro
phosphorylation of Rb protein by recombinant PKC (Upstate
Biotechnology, Lake Placid, NY) was performed as described
(26) with recombinant Rb protein (QED Bioscience, San Diego)
as a substrate.
Luciferase Assay. Luciferase reporter constructs (Mercury Cell
Cycle Profiling System, CLONTECH) were introduced into cells
with LipofectAMINE reagent (Life Technologies, Rockville,
MD) as instructed by the manufacturer. Luciferase activity was
measured by using the Dual-Luciferase Reporter Assay system
(Promega).
Results
Role of PKC in Ischemia-Induced Retinal Neovascularization. The
effects of PKC isoforms on ischemia-induced retinal neovas-
cularization were studied in the oxygen-induced retinopathy-of-
prematurity model by using PKC null mice (12) (PKC KO
mice) or transgenic mice overexpressing PKC2 isoform (PKC
Tg) in vascular tissues under preproendothelin promoter (9, 10),
which exhibited a 9-fold increase in PKC activity. Five days after
oxygen treatment, both wild-type and PKC Tg mice developed
retinal neovascularization as observed by fluorescein-perfused
retinal f lat mount (Fig. 1). However, a more extensive network
of neovascularization was observed in PKC Tg mice (Fig. 1b)
than with the wild type (B6FVB) (Fig. 1a). In contrast, much
less neovascularization was observed in the retina of PKC KO
mice (Fig. 1d) than with their respective control mice (B6129)
(Fig. 1c). No retinal neovascularization or significant morpho-
logical differences were observed in the vasculature of any
groups not receiving oxygen treatment (Fig. 1 e– h). No differ-
ences were observed in the extent of retinal capillary occlusion
in mice with oxygen treatment at postnatal day 12 (P12) (data
not shown).
Analysis of retinal cross-sections demonstrated that the num-
ber of endothelial cell nuclei anterior to the internal limiting
membrane (a measure of the extent of neovascularization)
decreased by 55% in PKC KO mice (Fig. 2c control, 2d-KO
mice) and increased by 3.2-fold in PKC Tg mice (Fig. 2 a,
control, and b, Tg mice) as compared with their respective
controls. These data suggested that activation of PKC2 isoform
contributed significantly to the development of neovasculariza-
tion in response to hypoxia. However, PKC2 isoform is not
essential for the angiogenic process during embryonic develop-
ment or growth, because both of these processes are normal in
PKC Tg and KO mice.
VEGF has been reported to be one of the main growth factors
inducing neovascularization in the oxygen-induced retinopathy
model (13). Thus, mRNA levels of VEGF and Flk1, a tyrosine
kinase receptor primarily mediating VEGF’s mitogenic actions
in endothelial cells, were measured by Northern blot analysis. No
differences were detected in the mRNA levels of VEGF or Flk1
in either PKC transgenic mice or knockout mice as compared
with their individual controls on postnatal day 14 (Fig. 2f ). These
data suggested that the angiogenic effects of PKC isoform are
potentially caused by enhancement of VEGF’s intracellular
action rather than by increasing the concentration of VEGF or
Flk1.
Role of PKC Isoforms in VEGF-Induced Angiogenic Responses. The
effects of various PKC isoforms on VEGF-induced cellular
proliferation and migration were correlated with several intra-
cellular signaling pathways in BREC. VEGF (0.6 nM) induced
a 2-fold increase in BREC total DNA content of BREC after 4
days. The addition of GFX (a general PKC inhibitor) and
PD98059 (a MEK inhibitor) blocked VEGF’s mitogenic activity
Fig. 1. Retinal vascular pattern by fluorescein-perfused retinal flat mount of
(a) wild-type and (b) PKC2 transgenic mice (FVBC57BL6); (c) wild type and
(d) PKC null mice (129sv  C57BL6), with (a–d) and without (e–h) oxygen
treatment. Five days after oxygen treatment (P17), fluorescence perfusion
showed that the vasculature was increased substantially in PKC 2 transgenic
mice and reduced in knockout mice as compared with wild-type mice. No
retinal neovascularization or morphological differences in the vasculature
were observed in the following groups without oxygen treatment; (e) wild-
type and ( f) PKC2 transgenic mice; (g) wild-type and (h) PKC knockout mice.
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completely (Fig. 3a) (2). The effects of each PKC isoform were
determined by infecting BREC with nonreplicating adenoviral
vectors containing either the wild-type or kinase-inactive
dominant-negative mutants of PKC , 1 and 2, , and 
isoforms. (PKC1 and 2 had similar effects in all studies with
BREC.) Only PKC isoforms enhanced VEGF-induced growth
in BREC, resulting in an 86% increase. Overexpression of
dominant-negative of PKC2 isoform inhibited PKC activity by
90% and decreased VEGF-induced growth by 68% (Fig. 3a),
suggesting that VEGF’s mitogenic activity in BREC depended
in part on PKC isoform and mitogen-activated protein kinase
pathway activation.
PKC activation also enhanced VEGF-induced BREC migra-
tion. VEGF (0.6 nM) increased migration of BREC 2-fold, an
effect inhibited by GFX, PD98059, and partially (41%) by
wortmannin [a phosphatidylinositol 3-kinase (PI3-kinase) inhib-
itor]. Overexpression of PKC , 2, , and  isoforms by
adenoviral vectors increased protein levels of these PKC iso-
forms by more than 10-fold; however, only PKC2 and 
isoforms enhanced VEGF-induced migration, by 100% and
145%, respectively. Overexpression of dominant-negative
PKC2 and  isoforms, as described above, inhibited VEGF-
induced BREC migration by 55% and 32%, respectively (Fig.
3b). In addition, overexpression of PKC2 and PKC isoforms
increased VEGF-induced mitogen-activated protein kinase (ex-
tracellular signal-regulated kinase; ERK12) phosphorylation
Fig. 2. Cross-sectional analysis of retina from (a) wild-type and (b) PKC2 transgenic mice; (c) wild-type and (d) PKC knockout mice. After retinal
neovascularization was induced by oxygen treatment (P17), sections of the eyes were evaluated for neovascularization (parenthesis or arrowhead). (e)
Quantification of retinal neovascularization (P17) by counting the neovascular cell nuclei. Vertical axis, number of nuclei anterior to the internal limiting
membrane per 6-m cross section (mean standard error of mean; data were calculated from 50 sections of five eyes). Symbols indicate significant differences
at P0.01 (†) and P0.001 (‡). ( f) Results were derived from Northern blot analysis of total RNA isolated from the retina of animals 2 days after oxygen treatment
and from age-matched normal controls (P14). Northern blots with 36B4 control (Upper) and quantification (Lower). Results were calculated from three separate
experiments.








by 61% and 74%, respectively (Fig. 3c), but did not increase
VEGF-induced PI3-kinase–Akt activation (data not shown).
These data indicated that both PKC and PKC isoforms
mediated VEGF-induced ERK12 activation and migration, but
only PKC isoform enhanced VEGF-induced endothelial cell
proliferation, suggesting that these PKC isoforms have both
common and distinct targets for their downstream actions.
Role of PKC in VEGF-Induced Rb-E2F Pathway Activation. Because
PKC activation, particularly the  isoforms, enhanced VEGF’s
mitogenic activity in BREC, we characterized the effect of
overexpressing PKC2 isoform on various signaling molecules
that regulate the progression of the cell cycle. VEGF and
overexpression of PKC2, but not PKC isoforms increased
basal phosphorylation of Rb (Fig. 4), a tumor suppressor that can
regulate cellular proliferation, differentiation, and death by
binding and inactivating the E2F transcriptional factor family
(27). As shown in Fig. 4 a and b, VEGF increased phosphory-
lation of Rb in a time-dependent manner by up to 3-fold at all
phosphorylation sites as quantified by various phospho-specific
antibodies (S249T252, S780, S795, S807S811, and S821).
Overexpression of PKC2 isoform by adenoviral vectors in-
creased basal- and VEGF-induced Rb phosphorylation at S780
and S795 (Fig. 4a) by more than 3-fold, but did not change
significantly the phosphorylation at S249T252, S807S811, or
S821 and did not alter the expression of cyclins or cyclin-
dependent kinase inhibitors (Fig. 4b). Overexpression of PKC
isoform did not significantly alter VEGF-induced phosphoryla-
tion of Rb.
To determine whether PKC2 isoform can associate and
phosphorylate Rb directly in BREC, immunoprecipitation stud-
ies were performed with anti-PKC2 antibody, and Rb protein
was detected by immunoblot analysis. At basal conditions, some
association of PKC2 isoform and Rb protein was observed. The
addition of VEGF and serum increased the association of
PKC2 with Rb by 2.2- and 2.6-fold, respectively. Overexpres-
sion of PKC2 dominant-negative mutant did not associate with
Rb (Fig. 4c). The same complex of PKC2 and Rb were
characterized with antibodies to pS780 of Rb, which showed a
basal phosphorylation with the overexpression of PKC2. The
addition of VEGF (0.6 nM) increased phosphorylated Rb levels
by 2- to 3-fold (Fig. 4c). Total cell lysates were immunoprecipi-
tated with antibodies to Rb protein and immunoblotted with
antibodies to PKC2. At basal conditions some associations of
PKC2 and Rb were observed, but the addition of VEGF (0.6
nM) increased the amount of PKC2- associated Rb protein by
1.7-fold (Fig. 4c). In vitro studies demonstrated that recombinant
PKC2 isoform phosphorylated Rb protein in the presence of
diacylglycerol and phosphatidylserine at S249T252, S780, S795,
and S821 sites (Fig. 4d). These data suggested that PKC2
isoform, when activated, could phosphorylate Rb protein at
multiple, but specific sites in an isoform-selective manner.
To determine whether PKC2 isoform could increase E2F
activity by the phosphorylation of Rb protein, the effect of
overexpressing PKC2 isoform on VEGF-induced E2F activa-
tion was evaluated by luciferase assay in BREC. VEGF and
overexpression of PKC2 independently increased E2F activity
by 8.6- and 3.7-fold, respectively. Overexpression of PKC2
increased VEGF’s effect by 49% (Fig. 4e). Again, overexpression
of PKC isoform was not effective, whereas overexpression of
PKC2 dominant-negative inhibited VEGF’s effect. Finally,
inhibition of E2F by E2F double-structured DNA decoy de-
creased VEGF-induced BREC proliferation in a dose-
dependent manner, with a maximum inhibition of 76% (Fig. 4f ).
Discussion
These studies have demonstrated that activation of the  iso-
forms of PKC can selectively enhance VEGF’s mitogenic effects
on endothelial cells and hypoxia-induced retinal neovasculariza-
tion. VEGF’s effect on endothelial cell growth differed from its
effect on migration, which involved PKC isoform and PI3-
kinase pathways. The mechanism of the mitogenic activity of
PKC isoforms on BREC includes the activation of ERK and
phosphorylation of Rb protein. These data have identified Rb
protein as a potential isoform-selective target of the activated
PKC2 isoform in the endothelial cells. The isoform selectivity
of PKC isoforms could be caused by their subcellular localiza-
Fig. 3. Role of PKC, PI3-kinase, ERK12, and specific PKC isoforms on
VEGF-induced growth and migration (mean standard deviation). VEGF (0.6
nM)-induced increases in (a) cell growth and (b) migration. (a) Cells were
incubated with vehicle, GFX (1 M), wortmannin (100 nM), PD98059 (20 M),
or infected with adenovirus (1.0  108 plaque-forming unitsml). After incu-
bation for 4 days at 37°C with or without VEGF (0.6 nM), the cells were lysed
in 0.1% SDS, and the DNA content was measured by means of Hoechst-33258
dye and a fluorometer (model TKO-100) to determine cell growth. (b) To
evaluate cell migration, a modified Boyden chamber migration assay with
BREC was performed. The top and bottom surface of the chamber membrane
was coated with collagen I. Serum-starved BREC overexpressing each PKC
isoform were induced to migrate toward VEGF (0.6 nM) placed in the bottom
chamber and harvested after 4 h. Cells that migrated to the bottom of the
chamber were enumerated by counting SYTOX green (Molecular Probes)
nucleic acid-stained cells. Overexpression of PKC1 had the same results as
PKC2 (data not shown). (c) Effects of individual PKC isoform on VEGF-induced
ERK phosphorylation. Cells overexpressing each PKC isoform were incubated
with VEGF (0.6 nM) for 10 min, and total proteins were separated by SDS-PAGE
and transferred to nitrocellulose membrane. Immunoblots were probed with
an antibody to phosphorylated ERK (Upper) and reprobed with antibody to
total ERK (Lower). Symbols indicate significant differences at P  0.05 (*),
P  0.01 (†), and P  0.001 (‡) vs. VEGF alone. Results were calculated from
three separate experiments and are presented as mean standard deviation.
724  www.pnas.orgcgidoi10.1073pnas.022644499 Suzuma et al.
Fig. 4. Effects of PKC2 isoform activation and VEGF on Rb phosphorylation and actions. (a) Time course of VEGF’s (0.6 nM) stimulation or the overexpression
of PKC2 or  isoforms. Phosphorylation of S780, S795, and S807S811 were quantified by phospho-specific antibodies. After the addition of VEGF, the cells were
harvested at each time point and total protein was separated by SDS-PAGE, transferred to nitrocellulose membrane, and analyzed with phospho-specific and
total Rb antibodies by immunoblot. (b) Effects of PKC2 overexpression on basal and VEGF-induced Rb phosphorylation at S780, S249T252, and S821, and the
pattern of expression of cyclin D1, E, A, and cyclin-dependent kinase inhibitors p27 and p21 were characterized after the addition of VEGF (0.6 nM) for 24 h. (c)
Interaction of PKC2 and Rb protein in vivo (Left and Right Upper). BREC overexpressing PKC2 were incubated with VEGF (0.6 nM) or 10% calf serum for 24 h.
Proteins were immunoprecipitated with anti-PKC2 antibodies and fractionated by SDS-PAGE. Immunoblots were probed with an antibody to Rb or
phosphoserine 780 (Top) and reprobed with antibody to PKC2 (Bottom) to determine whether PKC2 can associate directly with Rb (Right Lower). Cells were
incubated with VEGF (0.6 nM) for 24 h, and proteins were immunoprecipitated with anti-Rb antibodies and fractionated by SDS-PAGE. Immunoblots were probed
with an antibody to PKC2 (Top) and reprobed with antibody to Rb (Bottom) to determine whether Rb can associate directly with PKC2. (d) In vitro
phosphorylation of Rb by recombinant PKC2. PKC2 (0.2 M) was incubated with Rb protein (1.2 M) for 15 min at 30°C in the presence of Ca2 (1 mM),
phosphatidylserine (100g/ml), and diacylglycerol (1.3g/ml). The reaction was initiated by the addition of ATP (30M) with [-32P]ATP (30Ci/100 nmol). After
15 min, the reaction was terminated by the addition of Laemmli’s sample buffer. Samples were separated by SDS-PAGE, dried, and exposed to PhosphorImager
(Top), or transferred to nitrocellulose membrane, and analyzed with phospho-specific and total Rb antibodies by immunoblot. (e) Effects of VEGF and PKC on
E2F promoter activity. Cells were transfected with reporter constructs 24 h after adenovirus infection containing each PKC isoform or mutant, and stimulated
by VEGF (0.6 nM) for 9 h. Cells were harvested, and luciferase activity was measured. ( f) Cells were incubated for 4 days at 37°C with or without VEGF (0.6 nM)
after introduction of E2F (14 nucleotide base) decoy or mismatch control decoy. The cells were lysed in 0.1% SDS and the DNA content was measured. Symbols
indicate significant differences at P 0.05 (*), P 0.01 (†), and P 0.001 (‡). Results were calculated from three separate experiments and plotted as mean
standard deviation.








tion that can translocate to the nuclear membrane when acti-
vated (28).
VEGF clearly can phosphorylate multiple serine and threo-
nine sites on the Rb protein which are potential phosphorylation
sites of cyclin D and E kinases in retinal capillary endothelial
cells (29, 30). Phosphorylation of Ser-780, Ser-795, Ser-807,
Ser-811, and Thr-821 decreases the binding of Rb to E2F, which
would permit endothelial cells to progress from G1 to later stages
of the cell cycle (29–32). Activation of PKC2 isoform also
phosphorylated these serine and threonine sites, except Ser-807
and Ser-811 on the Rb in vitro. However, overexpression of
PKC2 isoform, but not the PKC or the PKC2 dominant-
negative isoforms, increased only the phosphorylation of Ser-780
and Ser-795 at the C-terminal of Rb but did not phosphorylate
other sites induced by PKC isoform in vitro or by VEGF. Brown
et al. (31) has reported that the loss of Ser-781 and the Ser-788
sites did not affect the binding of Rb to E2F-DNA. However, the
phosphorylation of these sites combined with other phosphor-
ylation sites in the N and C terminals affected by VEGF can alter
the binding and the promoter activities of E2F on transcription
(31, 32).
The results of the coprecipitation studies suggested that the
activated PKC2 but not its kinase-inactive dominant-negative
isoform can directly bind and phosphorylate Rb. It is also
possible that PKC2 isoform could indirectly phosphorylate
Ser-780 and Ser-785 of Rb by binding to cyclin E kinase, which
has been reported to bind and phosphorylate the same serine
sites of Rb (29). Further studies will be needed to decipher the
potential interactions of PKC isoforms with cyclin E kinase and
the definitive role of Ser-780 and Ser-795 phosphorylation on Rb
in mediating the enhancement of VEGF-induced endothelial
cell proliferation and retinal neovascularization. However, these
results have established that the activation of PKC isoforms can
selectively enhance the mitogenic action of VEGF and hypoxia-
induced retinal neovascularization potentially by directly binding
to and phosphorylating Rb and subsequently permitting activa-
tion of E2F to mediate transcription and cell cycle progression
in retinal endothelial cells.
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